TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02140762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.5 mL saline solution (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
Study: NCT02227901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01711333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pletaal SR capsule
Description: two capsules once a day of Pletaal SR 100mg Capsules
Study: NCT04050540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
Study: NCT04454840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma from healthy young people treatment + Riluzole
Description: Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: The basic treatment is Riluzole 25\~50mg twice daily
Study: NCT00545740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476 (1.2g)
Description: 1.2g SPD476 once daily (QD) orally
Study: NCT02238340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipirone
Study: NCT01973595

Intervention type: OTHER
Group type: OTHER
Intervention: No Almonds, Then almonds
Description: No almonds will be consumed by participants for 3 weeks.
Study: NCT05972148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital scanning
Description: Five intraoral scans, one for each arch before the insertion of scanbodies, were obtained. The implant locations were then marked, and the software trimmed a 6mm diameter circular section of the scan from the implant locations to allow the scanbodies to be added. Abutment-level polyetheretherketone (PEEK) scanbodies were hand-tightened onto each implant and not moved for the remainder of the scans. Scanbodies were scanned using a circular scan path, and scanning was finalized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photogrammetry
Description: Rectangular-shaped titanium photogrammetry scanbodies were hand-tightened onto the Implants. Scanbodies were not moved before completing all scans for each arch. A total of five scans of each arch were obtained using a photogrammetry device. Measurements were successfully recorded by turning them green on the computer screen.
Study: NCT02201277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filter Placed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filter Placed
Study: NCT03486665

Intervention type: OTHER
Intervention: Blood Sampling
Description: Blood samples will be taken from all patients and healthy volunteers.

Intervention type: OTHER
Intervention: Blood Sampling
Description: Blood samples will be taken from all patients and healthy volunteers.

Intervention type: OTHER
Intervention: Blood Sampling
Description: Blood samples will be taken from all patients and healthy volunteers.

Intervention type: OTHER
Intervention: CSF Sampling
Description: CSF sample will be taken from hospitalized newly diagnosed patients only.
Study: NCT03576079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anterior re-positioning splint
Description: hard acrylic anterior re-positioning splint

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: inactive Laser therapy
Description: sham Laser, with inactive beam
Study: NCT02466685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-18038683
Description: JNJ-18038683 10-20 mg/day tablet for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet daily
Study: NCT03777163

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Butantan Institute Trivalent Seasonal Influenza Vaccine
Description: Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
Study: NCT00989118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment of ovarian endometrioma
Description: Laser vaporization of ovarian endometrioma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment of ovarian endometrioma
Description: Laser vaporization of ovarian endometrioma
Study: NCT03773497

Intervention type: OTHER
Group type: OTHER
Intervention: Common Snack Combination
Description: Combination of Chips, Pretzels, and Popcorn.

Intervention type: OTHER
Group type: OTHER
Intervention: Cheesy Broccoli Snack
Description: Oven-roasted, freeze-dried, cheese flavored broccoli

Intervention type: OTHER
Group type: OTHER
Intervention: Cheesy Broccoli with Daikon Radish Snack
Description: Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder

Intervention type: OTHER
Group type: OTHER
Intervention: Uncooked Broccoli Snack
Description: Uncooked, freeze-dried broccoli with ranch-type dip
Study: NCT03681132

Intervention type: OTHER
Group type: OTHER
Intervention: Stop of therapy
Description: The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.

Intervention type: OTHER
Group type: OTHER
Intervention: Stop of therapy
Description: The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
Study: NCT03692845

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transforaminal Lumbar Interbody Fusion either open or minimally invasive
Description: Spinal fusion procedure through the intervertebral foramen

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transforaminal Lumbar Interbody Fusion either open or minimally invasive
Description: Spinal fusion procedure through the intervertebral foramen
Study: NCT03777163

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sanofi Trivalent Seasonal Influenza Vaccine
Description: VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (\> 60 years),11,12 children (six months to three years) 13 and pregnant women.
Study: NCT05968417

Intervention type: OTHER
Intervention: Observational study - sample collection only.
Description: No intervention - blood and/or bone marrow sample collection only
Study: NCT02234219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart-shape anastomosis
Description: a new operation approach for Hirschsprung disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soave anastomosis
Description: traditional approach for Hirschsprung disease
Study: NCT01658501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PB1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride)
Study: NCT02238340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexametasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexametasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine IV (rescue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine IV (rescue)
Study: NCT04787068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy support
Description: Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
Study: NCT04159363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)
Description: The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
Study: NCT02659553

Intervention type: PROCEDURE
Intervention: steatosis
Description: Liver Transplantation with graft steatosis

Intervention type: PROCEDURE
Intervention: steatosis
Description: Liver Transplantation with graft steatosis

Intervention type: PROCEDURE
Intervention: steatosis
Description: Liver Transplantation with graft steatosis
Study: NCT00866671

Intervention type: DRUG
Intervention: nelarabine
Description: Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
Study: NCT01811576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human growth hormone
Description: Subcutaneous once daily
Study: NCT06184841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC combined with intravenous PD-1
Description: Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
Study: NCT04159532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAG-EPA/MAG-DHA
Description: monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TG-EPA/TG-DHA
Description: Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EE-EPA/EE-DHA
Description: Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
Study: NCT01460407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Administered orally
Study: NCT03301064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)
Description: Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol education brochure
Description: The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol education brochure
Description: The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
Study: NCT00612625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucagon-like peptide-1
Description: continuous infusion of GLP-1 (1½ pmol/kg/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: continuous infusion of saline
Study: NCT04911712

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: a hospital formula of normal protein liquid diet supplementation
Description: group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a hospital formula of high protein liquid food supplementation
Description: group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
Study: NCT03675542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-305
Description: Dose-selection treatment with HSP90 inhibitor (CUDU-305)
Study: NCT03419390

Intervention type: DEVICE
Group type: OTHER
Intervention: combined Coaxial Optical Coherence Tomography (OCT) System
Description: The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel

Intervention type: DEVICE
Group type: OTHER
Intervention: combined Coaxial Optical Coherence Tomography (OCT) System
Description: The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel

Intervention type: DEVICE
Group type: OTHER
Intervention: combined Coaxial Optical Coherence Tomography (OCT) System
Description: The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
Study: NCT01107561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seldinger technique
Description: Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Airway Approach
Description: The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
Study: NCT04868487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Literacy Education
Description: Health literacy education, consisting of four sessions, was given to the intervention group.
Study: NCT02385916

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EstroSense®/MD
Description: A natural product already approved by Health Canada

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00844805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Study: NCT04557787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath® Standard female
Description: Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 1 catheter for females
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 2 catheter for females
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
Study: NCT00857948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin treatment conditioner
Description: Application followed by thorough rinsing of the hair and scalp with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin treatment conditioner
Description: Application followed by thorough rinsing of the hair and scalp with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin treatment conditioner
Description: Application followed by thorough rinsing of the hair and scalp with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, vehicle control
Description: Application followed by thorough rinsing of the hair and scalp with water.
Study: NCT03738384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Connect + Visual Feedback System
Description: A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
Study: NCT03857321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly \& Company)
Study: NCT00545740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476 (2.4 g)
Description: 2.4g SPD476 QD orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476 (4.8 g)
Description: 4.8g SPD476 QD orally
Study: NCT01658501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% Sodium Chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride)
Study: NCT01012206

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention regarding food habits and physical activity.
Description: Children in the intervention group participated in an intervention program regarding food habits and physical activity.
Study: NCT03710239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilapan-S
Description: Synthetic osmotic dilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria
Description: Seaweed-based osmotic dilator
Study: NCT01889134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedron (alendronate)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroidectomy
Study: NCT04135859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Lifestyle Intervention
Description: Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Monitoring
Description: A physical activity monitor (Fitbit) will be provided to both groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Monitoring
Description: A physical activity monitor (Fitbit) will be provided to both groups.
Study: NCT03299231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPEP Aerobika
Description: Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: OPEP Aerobika Sham device
Description: The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
Study: NCT00918268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
Study: NCT02073357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light general anaesthesia (BIS = 50)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep general anaesthesia (BIS = 35)